Preclinical Evaluation of a Novel Small Molecule Inhibitor of LIM Kinases (LIMK) CEL_Amide in Philadelphia-Chromosome Positive (<i>BCR::ABL+</i>) Acute Lymphoblastic Leukemia (ALL)

Preclinical Evaluation of a Novel Small Molecule Inhibitor of LIM Kinases (LIMK) CEL_Amide in Philadelphia-Chromosome Positive (<i>BCR::ABL+</i>) Acute Lymphoblastic Leukemia (ALL)

Ph+ (<i>BCR::ABL+</i>) B-ALL was considered to be high risk, but recent advances in <i>BCR::ABL</i>-targeting TKIs has shown improved outcomes in combination with backbone chemotherapy. Nevertheless, new treatment strategies are needed, including approaches without chemothera...

Full description

Bibliographic Details
Main Authors: Jeannig Berrou, Mélanie Dupont, Hanane Djamai, Emilie Adicéam, Véronique Parietti, Anna Kaci, Emmanuelle Clappier, Jean-Michel Cayuela, André Baruchel, Fabrice Paublant, Renaud Prudent, Jacques Ghysdael, Claude Gardin, Hervé Dombret, Thorsten Braun
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Journal of Clinical Medicine
Subjects:
LIM kinase
CEL_Amide
<i>BCR::ABL</i>
ALL
tyrosine kinase inhibitors
Online Access:https://www.mdpi.com/2077-0383/11/22/6761

Internet

https://www.mdpi.com/2077-0383/11/22/6761

Similar Items